Cue Biopharma (CUE) Research & Development (2017 - 2026)
Cue Biopharma's Research & Development came in at $49.01 million for Q2 2026, up 519.6% from $7.91 million a year earlier.
Powered by 
Analysis
Cue Biopharma (CUE) Research & Development (2017 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Cue Biopharma reported Research & Development of $78.2 million, up 136.8% year-over-year; for FY2025, it came in at $37.74 million, up 4.0% from FY2024.
- Research & Development carries a five-year compound annual growth rate of 2.4% (FY2020 to FY2025).
- Going back by year, Research & Development was $36.3 million in FY2024 (-11.0%), $40.8 million in FY2023 (+5.8%), $38.58 million in FY2022 (-6.7%) and $41.35 million in FY2021 (+23.3%).
- The Q2 2026 figure represents the highest quarterly Research & Development in data going back to Q1 2017.
- Year-over-year, Research & Development increased in two of the last seven quarters, with growth averaging 75.5%.
- The fastest year-over-year change in Research & Development over five years came in Q2 2026 (growth of 519.6%), and the weakest in Q3 2025 (a decline of 49.3%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Cue Biopharma | 121.14 Mn | 30.41 Mn | - | 49.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.01 Mn |
| Dec 31, 2025 | 16.53 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 7.91 Mn |
| Mar 31, 2025 | 8.55 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 9.38 Mn |
| Jun 30, 2024 | 9.53 Mn |
| Mar 31, 2024 | 10.20 Mn |
| Dec 31, 2023 | 10.89 Mn |
| Sep 30, 2023 | 9.87 Mn |
| Jun 30, 2023 | 10.65 Mn |
| Mar 31, 2023 | 9.39 Mn |
| Dec 31, 2022 | 11.33 Mn |
| Sep 30, 2022 | 7.57 Mn |
| Jun 30, 2022 | 9.59 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 11.50 Mn |
| Sep 30, 2021 | 11.29 Mn |
| Jun 30, 2021 | 8.76 Mn |
API Access
Cue Biopharma Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=CUE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "CUE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=CUE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();